PRKCB and prostate adenocarcinoma: Consistent with our findings, significantly lower expression levels of ADAMTS12, CCDC181, NAALAD2, as well as PRKCB were identified in PCa as compared to NPT in the PRAD cohort (all p < 0.0500), except for ZMIZ1 (p > 0.0500; Figure S2).